#clinical trials

15 Oct 2026

Compass Pathways Prepares Psilocybin Therapy for FDA Review

Compass Pathways CEO warns a cautious rollout to protect the emerging psychedelic field as the company finalizes its FDA submission for COMP360.

Read more